Elanco partners with Medgene to launch HPAI vaccine for dairy cattle
Source: dairynews.today
Elanco Animal Health collaborates with Medgene to introduce the first highly pathogenic avian influenza (HPAI) vaccine specifically designed for dairy cattle, aiming to curb virus transmission and maintain herd health.
Elanco Animal Health has joined forces with Medgene to introduce a pioneering vaccine against highly pathogenic avian influenza (HPAI) for dairy cattle. The collaboration marks a significant step towards enhancing animal health and preventing the spread of the virus, which has affected more than 970 dairy farms with newly confirmed cases.
Tim Bettington, Executive Vice President for Elanco, emphasized the vaccine's potential impact, stating, "Our ability to vaccinate those animals and potentially eliminate transmission means healthier animals. It’s reduced milk production, reduced profitability and value for the dairy producer themselves." He highlighted the alliance's rapid progress and the ongoing process for obtaining conditional license approval, though a specific date for availability remains unspecified.
According to the USDA’s Animal and Plant Health Inspection Service, the spread of HPAI poses a considerable threat to dairy cattle health and farm productivity. Bettington anticipates that the collaboration with Medgene will address this challenge effectively.
Tim Bettington, Executive Vice President for Elanco, emphasized the vaccine's potential impact, stating, "Our ability to vaccinate those animals and potentially eliminate transmission means healthier animals. It’s reduced milk production, reduced profitability and value for the dairy producer themselves." He highlighted the alliance's rapid progress and the ongoing process for obtaining conditional license approval, though a specific date for availability remains unspecified.
According to the USDA’s Animal and Plant Health Inspection Service, the spread of HPAI poses a considerable threat to dairy cattle health and farm productivity. Bettington anticipates that the collaboration with Medgene will address this challenge effectively.
